Health Care & Life Sciences » Pharmaceuticals | Nordic Nanovector ASA

Nordic Nanovector ASA | Income Statement

Fiscal year is January-December. All values NOK Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
306.10
439.50
437.00
314.00
302.00
2,252
Cost of Goods Sold (COGS) incl. D&A
18,417.20
69,109.10
61,269.00
-
-
2,252
Gross Income
18,111.10
68,669.60
60,832.00
-
-
2,252
SG&A Expense
-
-
-
228,869.00
329,564.00
347,069
EBIT
18,111.10
68,669.60
190,332.00
-
330,745.00
349,321
Non Operating Income/Expense
-
365.10
5,459.00
9,847.00
31,452.00
7,791
Interest Expense
106.70
-
-
-
-
-
Pretax Income
17,010.90
63,628.90
172,677.00
235,171.00
293,433.00
336,972
Income Tax
-
44.00
398.00
339.00
381.00
800
Consolidated Net Income
17,010.90
63,672.90
173,075.00
235,510.00
293,814.00
337,772
Net Income
17,010.90
63,672.90
173,075.00
235,510.00
293,814.00
337,772
Net Income After Extraordinaries
17,010.90
63,672.90
173,075.00
235,510.00
293,814.00
337,772
Net Income Available to Common
17,010.90
63,672.90
173,075.00
235,510.00
293,814.00
337,772
EPS (Basic)
0.64
3.54
4.28
5.26
5.99
6.86
Basic Shares Outstanding
26,550.30
17,964.50
40,443.20
44,776.20
49,030.70
49,242.50
EPS (Diluted)
0.64
3.54
4.28
5.26
5.99
6.86
Diluted Shares Outstanding
26,550.30
17,964.50
40,443.20
44,776.20
49,030.70
49,242.50
EBITDA
17,874.30
68,324.20
189,338.00
228,555.00
329,262.00
347,069
Other Operating Expense
-
-
129,500.00
-
-
-
Non-Operating Interest Income
1,206.90
4,675.60
12,196.00
4,391.00
5,860.00
4,558

About Nordic Nanovector ASA

View Profile
Address
Kjelsasveien 168 B
Oslo PS 0884
Norway
Employees -
Website http://www.nordicnanovector.com
Updated 07/08/2019
Nordic Nanovector ASA engages in the provision of development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers such as non-Hodgkin's Lymphoma and leukaemia. It offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. Nordic Nanovector operates its business through the following geographical segments: Norway, Switzerland, and the United Kingdom.